May 12, 2023 8:00am EDT SCYNEXIS Reports Closing of Exclusive License Agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets)
May 11, 2023 7:00am EDT SCYNEXIS Announces First Quarter 2023 Financial Results and Provides Corporate Update